Heat Shock Proteins HSP27 and HSP70 Are Present in the Skin and Are Important Mediators of Allergic Contact Hypersensitivity

Nabiha Yusuf, Tahseen H. Nasti, Chun-Ming Huang, Brad S. Huber, Tarannum Jaleel, Hui-Yi Lin, Hui Xu and Craig A. Elmets

*J Immunol* 2009; 182:675-683; doi: 10.4049/jimmunol.182.1.675
http://www.jimmunol.org/content/182/1/675

**References**  This article cites 43 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/182/1/675.full#ref-list-1

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Heat Shock Proteins HSP27 and HSP70 Are Present in the Skin and Are Important Mediators of Allergic Contact Hypersensitivity

Nabiha Yusuf,* Tahseen H. Nasti,* Chun-Ming Huang,* Brad S. Huber,* Tarannum Jaleel,* Hui-Yi Lin,* Hui Xu,* and Craig A. Elmets**

Proteomic analysis of murine skin has shown that a variety of heat shock proteins (HSPs) are constitutively expressed in the skin. Using murine allergic contact hypersensitivity as a model, we investigated the role of two heat shock proteins, HSP27 and HSP70, in the induction of cutaneous cell-mediated immune responses. Immuno-histochemical examination of skin specimens showed that HSP27 was present in the epidermis and HSP70 was present in both the epidermis and dermis. Inhibition of HSP27 and HSP70 produced a reduction in the 1-fluoro-2,4-dinitrobenzene contact hypersensitivity response and resulted in the induction of Ag-specific unresponsiveness. Treatment of dendritic cell cultures with recombinant HSP27 caused the up-regulation of IL-1β, TNF-α, IL-6, IL-12p70, and IL-12p40 but not IL-23p19, which was inhibited when Abs to HSP27 were added. The 1-fluoro-2,4-dinitrobenzene-conjugated dendritic cells that had been treated with HSP27 had an increased capacity to initiate contact hypersensitivity responses compared with control dendritic cells. This augmented capacity required TLR4 signaling because neither cytokine production by dendritic cells nor the increased induction of contact hypersensitivity responses occurred in TLR4-deficient C3H/HeJ mice. Our findings indicate that a cascade of events occurs following initial interaction of hapten with the skin that includes increased activity of HSPs, their interaction with TLR4, and, in turn, increased production of cytokines that are known to enhance Ag presentation by T cells. The results suggest that HSPs form a link between adaptive and innate immunity during the early stages of contact hypersensitivity. The Journal of Immunology, 2009, 182: 675–683.
immunopathology of the skin has not been investigated. Using murine allergic contact hypersensitivity (CHS) as a model, the studies presented here were designed to examine the role of HSP27 and HSP70, two HSPs that are expressed in the skin, in the induction of cutaneous cell-mediated immune responses. We found that inhibition of HSP27 and HSP70 retarded the development of CHS to 1-fluoro-2,2-dinitrobenzene (DNFB) and led to the induction of tolerance to that hapten. We also observed that HSP27 treatment of dendritic cells (DCs) led to an increase in the secretion of several cytokines that are known to be involved in Ag presentation to T cells and an augmented capacity to initiate CHS responses. Finally, we found that the effect of HSPs on DCs did not occur in TLR4-deficient mice, indicating that components of the innate immune system were required for HSP27 effects.

Materials and Methods

Animals and reagents

Adult female, 6- to 8-wk-old C3H/HeN mice were obtained from Charles River Laboratories and adult female, 6- to 8-wk-old C3H/HeJ mice were purchased from The Jackson Laboratory. Animals were maintained in accordance with institutional guidelines.

Normal goat IgG and goat polyclonal anti-HSP27 and anti-HSP70 IgG were purchased from Santa Cruz Biotechnology. Alexa Fluor 488-conjugated donkey anti-goat IgG, Alexa Fluor 594-conjugated goat anti-rabbit IgG, and Texas Red X-phalloidin and sheep anti-rat IgG Dynabeads were from Invitrogen. Hybridoma lines GK1.5 (anti-CD4), Lyt-2 (anti-CD8), and HB-32 (anti-Ia<sup>+</sup>) were acquired from American Type Culture Collection. CD3e, CD45R/B220, and recombinant GM-CSF were obtained from BD Pharmingen. Recombinant HSP25 (The 27-kDa HSP was originally named as HSP25 in mice; in this manuscript, the molecule will be termed HSP27) was purchased from Calbiochem. DNFB, 2,4-dinitrobenzenesulfonic acid (DNBS), LPS, polymyxin B, and IL-4 and were purchased from Sigma-Aldrich.

Immunofluorescent staining

Staining for HSP27 and HSP70 was done as described in our previous studies (6). Briefly, fixed skin sections were incubated with anti-HSP27/anti-HSP70 primary Ab and were then treated with Alexa Fluor 488-conjugated donkey anti-goat IgG; tissues incubated with Texas Red X-phalloidin and sheep anti-rat IgG Dynabeads were from Invitrogen. Hybridoma lines GK1.5 (anti-CD4), Lyt-2 (anti-CD8), and HB-32 (anti-Ia<sup>+</sup>) were acquired from American Type Culture Collection. CD3e, CD45R/B220, and recombinant GM-CSF were obtained from BD Pharmingen. Recombinant HSP25 (The 27-kDa HSP was originally named as HSP25 in mice; in this manuscript, the molecule will be termed HSP27) was purchased from Calbiochem. DNFB, 2,4-dinitrobenzenesulfonic acid (DNBS), LPS, polymyxin B, and IL-4 and were purchased from Sigma-Aldrich.

Ab application on skin

To assess the contribution of HSP27 and 70 in CHS, the abdominal skin of mice was treated with some modifications (16). Briefly, bone marrow cells from femurs and tibiae were incubated in RPMI 1640 medium with a mixture of Abs against Ia<sup>+</sup>, CD45R/B220, Lyt-2, and GK1.5 (2 μg/10<sup>6</sup> cells) on ice for 1 h and washed once with HBSS after lysis of RBCs. Different cellular populations were removed from the cell suspension by Ab-mediated depletion using sheep anti-rat IgG Dynabeads according to the manufacturer’s instructions.

Cells were washed once with HBSS and cultured in 10% FCS/RPMI 1640 medium supplemented with recombinant mouse GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) in 6-well plates (5 x 10<sup>6</sup> cells/well). On day 5, one-half of the medium was replaced with fresh medium and cells were stimulated on the following day for the experiments.

Stimulation of DNFB-primed lymph node cells with hapten-conjugated BMDC for cytokine production

To assess Ag-specific cytokine production, BMDC were used for in vitro stimulation of primed lymph node cells as described elsewhere (14). Briefly, mice were pretreated with anti-HSP27/70 or species-matched control Ab as described earlier and were then sensitized with DNFB in a 41 mixture of olive oil:acetone on day 0. On day +5, mice were sacrificed and lymph node cell suspensions were prepared by gentle pressure through a wire mesh screen. Ten million BMDC were suspended in 1 ml of DNBS solution (5 mM in PBS) for 15 min. The cells were then washed three times with RPMI 1640 containing 5% FCS and resuspended in the culture medium. DNFB-primed lymph node cells (2 x 10<sup>6</sup>/ml) were stimulated with DNBS-labeled BMDC (2 x 10<sup>5</sup>/ml). Cytokine concentrations in culture supernatants were measured 48 h after cultures by cytokine-specific ELISA.

Assessment of tolerance

Tolerance to DNFB was assessed by a modification from the protocol of Schwarz et al. (17). On day –14, the abdominal skin of mice was treated as described above for Ab application on the skin. Two micrograms of control Ab, anti-HSP27, anti-HSP70, or a combination of anti-HSP27 and anti-HSP70 Abs in PBS were applied to the skin for 2 h under occlusion with a bioocclusive dressing. Immediately thereafter, 25 μl of 0.5% DNFB was applied topically to the Ab-treated site. On day 0, mice were resected on the dorsal side and 5 l of 0.2% DNFB or 1% oxazolone were applied to the Ab-treated site. On day 14, but on the shaved dorsal side and 5 l on each footpad. On day 0 they were sensitized with 50 l of 0.5% DNFB on the shaved dorsal site and 5 l on each footpad. On day +5, hapten-sensitized and control mice were challenged with 20 μl of 0.2% DNFB or 1% oxazolone on the ear. The increase in ear swelling was measured at 24-h intervals as described above.

To evaluate antigenic specificity of tolerance, mice were treated in the same manner as above. One group of anti-HSP27- and anti-HSP70 Ab-treated mice was sensitized with 25 μl of 0.5% DNFB on day –14, but on day 0 they were sensitized with 50 l of 3% oxazolone on their shaved dorsal side and 5 l on each footpad. On day +5, hapten-sensitized and control mice were challenged with 20 μl of 0.2% DNFB or 1% oxazolone on the ear. The increase in ear swelling was measured at 24-h intervals as described above.

Adaptive transfer of regulatory cells

Mice were treated epicutaneously with 2 μg of control or anti-HSP27 and anti-HSP70 Ab on their shaved abdomen for 2 h as described above in Ab application on the skin. Subsequently, 25 μl of 0.5% DNFB was applied topically to the abdomen on the Ab-treated site. On day +5, donor mice from the two groups were sacrificed and single-cell lymphocyte suspensions were prepared from draining lymph nodes. Lymph node cells, 50 x 10<sup>6</sup> in 200 μl of PBS, were injected i.v. into the tail vein of naive recipient mice. The recipients were contact sensitized immediately after adoptive transfer of the lymph node cells with 25 μl of 0.5% DNFB on the shaved skin. The recipients were then injected i.v. with 25 l of 0.5% DNFB on the shaved skin. The recipients were then injected i.v. with 25 l of 0.5% DNFB on the shaved skin.
On day +100, they were challenged with 20 μl of 0.2% DNFB on the ear. The increase in ear swelling was measured at 24-h intervals as described above.

In vitro stimulation of BMDC with HSP27

BMDC were stimulated with 1 μg/ml recombinant HSP27. LPS was used as a positive control for inducing DC maturation. Polymyxin B (10 μg/ml) was added to the samples before stimulation to prevent LPS contamination. After 24 h of culture at 37°C in the presence of 5% CO₂, culture supernatants were collected and stored at −20°C until cytokine measurements were performed.

In vitro measurement of cytokine production

Cytokine concentrations in culture supernatants from stimulated BMDC were measured using cytokine-specific ELISA kits from Invitrogen according to the manufacturer’s instructions.

Assessment of CHS response after injection of hapten-labeled BMDC

BMDC (naive and HSP27 stimulated) from C3H/HeN and C3H/HeJ mice were labeled with DNBS according to previously established protocols, with some modifications (14). Ten million cells were suspended in 1 ml of DNBS solution (5 mM in PBS) for 15 min. The cells were then washed three times with RPMI 1640 containing 5% FCS and resuspended in the culture medium. One million cells were injected s.c. on the right and left ventral side of each group of mice. Later, the mice were ear challenged with 20 μl of 0.2% DNFB. The positive control groups were sensitized with 25 μl of 0.5% DNFB and on day +5 they were ear challenged with 20 μl of 0.2% DNFB. The increase in ear swelling was measured at 24-h intervals as described above.

Statistical analysis

Data were analyzed by one-tailed Student’s t test, and the p values are indicated in the text and figure legends. The group difference was compared using the ANOVA test followed by Tukey’s post hoc test for multiple comparison adjustment in one experiment. Differences were considered significant at p < 0.05.

FIGURE 3. CHS to DNFB is inhibited by pretreatment of skin with Abs to HSPs 27 (HSP27) and 70 (HSP70). A, C3H/HeN mice were treated with anti-HSP Abs (2 μg/mouse in 100 μl of PBS). After 2 h, the mice were sensitized with DNFB on the Ab-treated site. The mice were ear challenged 5 days later and auricular thickness was measured at 24 h. The application of anti-HSP Abs significantly inhibited the CHS response (*, p < 0.05). Results were expressed as change in auricular thickness ± SEM. There were four mice per group and each experiment was repeated twice with the same results. The results are from one representative experiment. The group difference was compared using the ANOVA test followed by Tukey’s post hoc test for multiple comparison adjustment. B, Histologic sections were taken from representative mice at 24 h after DNFB challenge, stained with H&E, and photomicrographs were taken (original magnification, ×10 for all sections).
Results

Localization of HSP27 and HSP70 in the murine skin

In previous studies, proteomic analysis of the skin of C3H/HeN and BALB/c mice revealed that there was constitutive expression of the heat shock proteins HSP27 and HSP70 (6). To identify where in the skin these molecules were expressed, sections of skin were subjected to immunohistochemical analysis. HSP27 was only detected in the superficial layers of epidermis, whereas HSP70 was present throughout the entire epidermis and also to some extent in the dermis (Fig. 1).

It has been demonstrated that under certain conditions, topically applied proteins and DNA can reach deeper levels of the skin (18–21). To determine whether the procedures we had used allowed Ab to penetrate, Ab was applied to the skin under a bioocclusive dressing as described in Materials and Methods. By immunohistochemical analysis, the Ab could only be detected in the superficial layers of epidermis after 15 min. But with greater lengths of time up to 4 h, the Ab had penetrated to the dermis and s.c. tissue (Fig. 2).

Heat shock proteins HSP27 and HSP70 play a role in CHS response to DNFB

Having determined that Abs could penetrate into the epidermis and dermis, experiments were performed to assess the functional relevance of HSP27 and HSP70 in cutaneous cell-mediated immune responses. To do this, C3H/HeN mice were contact sensitized to DNFB after anti-HSP27 and anti-HSP70 Abs had been applied topically to abdominal skin that had been prepared in the manner described above. Inhibition of the induction of DNFB CHS could be achieved by pretreatment with both anti-HSP27 and anti-HSP70 Abs (Fig. 3). When both anti-HSP27 and anti-HSP70 Abs were applied simultaneously, there was an additive effect leading to greater inhibition of CHS than with either alone (Fig. 3). When goat IgG was used as a species-matched control, there was no inhibition, indicating that the effect of topical Ab treatment was specific for the anti-HSP Abs used (Fig. 3). Inhibition of the induction of DNFB CHS with anti-HSP27 was dose dependent with maximum inhibition occurring at 2 μg/mouse. Similar results were obtained with anti-HSP70 (data not shown).

Studies on the contact hypersensitivity response to DNFB have demonstrated that this response is mediated by IFN-γ and IL-17 in mice (14, 22). Experiments were therefore also performed in which hapten-primed lymph node cells were isolated from the draining lymph nodes of DNFB-sensitized mice and placed in culture with DNBS-labeled BMDC. This served as an alternative method of assessing the immune response to topically applied hapten. Hapten-labeled BMDC stimulated the production of IL-17 and IFN-γ by primed lymph node cells, whereas they were not able to stimulate naive lymph node cells (Fig. 4). Pretreatment of mice with anti-HSP27 and anti-HSP70 Ab significantly inhibited the production of IL-17 and IFN-γ compared with untreated BMDC (Fig. 4, p < 0.05). We also observed a corresponding increase in...
IL-4 and IL-10 production under the same conditions. It is possible that treatment of anti-HSP27 and anti-HSP70 Ab shifts the response from a Th1/Th17 to a Th2 phenotype at least in vitro.

Inhibition of CHS to DNFB by anti-HSP Abs is a local effect of the Abs

To assess whether the effect of topically applied anti-HSP Abs was a local or systemic one, separate panels of mice were treated with anti-HSP27 or anti-HSP70 on the abdomen or the back, and attempts were then made to sensitize both panels of mice on the abdomen. Mice that had been treated with anti-HSP27 or anti-HSP70 on the abdomen, showed significant inhibition of the DNFB CHS response (Fig. 5), confirming the results shown in Fig. 3. In contrast, mice treated with anti-HSP Ab on the back, but having received a sensitizing dose of DNFB on the abdomen, had no inhibition of CHS (p > 0.05). These results show that the inhibitory effect of topical application of this dose of anti-HSP Abs is a local occurrence, restricted to the site of Ab treatment.

Induction of hapten-specific tolerance by HSP-27 and -70 Abs

Experiments were then conducted to determine whether epicutaneous application of anti-HSP Ab followed by DNFB application had an effect on subsequent attempts to sensitize mice to that hapten. Animals that had been sensitized with DNFB on anti-HSP Ab-treated skin were resensitized with 0.5% DNFB after a resting period of 14 days and were then ear challenged with DNFB 5 days after that. The ear swelling response of mice pretreated with anti-HSP Ab was suppressed compared with positive controls despite the fact that the second attempt to sensitize mice was through normal skin (Fig. 6). This indicated that mice treated with anti-HSP Ab followed by hapten application had become tolerant to DNFB.

To determine whether suppression of the induction of CHS was hapten specific and to exclude the possibility that the mice treated with a combination of anti-HSP27 and anti-HSP70 Abs and hapten were also nonresponsive to other haptens given subsequently, the following experiment was performed. Panels of mice were treated with a combination of anti-HSP27 and anti-HSP70 Abs followed immediately thereafter by application of DNFB to the Ab-treated site. Two weeks later, animals were treated with either a sensitizing dose of DNFB or a different hapten (oxazolone). Five days

FIGURE 5. Application of anti-HSP Abs to the skin inhibits CHS to DNFB through a local effect. C3H/HeN mice were treated with anti-HSP27 or anti-HSP70 Ab on the abdomen or back as indicated. All mice, with the exception of the negative control, were then sensitized with DNFB on the abdomen. Application of hapten to the Ab-treated site produced significant inhibition of the CHS response (**, p < 0.001). In contrast, administration of anti-HSP27 or HSP70 Abs to the back but with hapten sensitization to the abdomen resulted in an ear swelling response that was not significantly different (p > 0.05) from the PBS-treated control. Results are expressed as change in auricular thickness ± SEM. There were four mice per group and each experiment was repeated twice with identical results. The data shown are from one representative experiment.

FIGURE 6. Application of DNFB to sites of HSP treatment renders mice tolerant to that hapten. C3H/HeN mice were treated with HSP Ab on the shaved abdomen. DNFB was applied to the Ab site as described elsewhere. Fourteen days later, mice were sensitized with DNFB on the shaved back and were subsequently ear challenged after 5 days. Ear swelling responses indicate that the inhibition of CHS response produced by the HSP Ab persisted and was significant (*, p < 0.05 and **, p < 0.001) in these mice. Results are expressed as change in auricular thickness ± SEM. There were four mice per group and each experiment was repeated twice with identical results. The data shown are from one representative experiment.

FIGURE 7. Tolerance to DNFB following HSP Ab treatment is Ag specific. C3H/HeN mice were treated with HSP Ab on the abdomen, after which 0.5% DNFB was applied to the same site. After 14 days, the mice were resensitized on the shaved back with either 0.5% DNFB or 3% oxazolone. Mice were ear challenged 5 days later with the same hapten that had been applied to the back. Ear swelling responses indicate that the inhibition of the CHS response produced by the HSP Ab was present in the DNFB back-sensitized group (*, p < 0.05), but was not present in the oxazolone back-sensitized mice (p > 0.05). Results are expressed as change in auricular thickness ± SEM. There were four mice per group and each experiment was repeated twice with identical results. The data shown are from one representative experiment.
FIGURE 8. Inhibition of DNFB CHS by anti-HSP Abs can be adoptively transferred by splenocytes. C3H/HeN mice were treated with either a combination of anti-HSP27 and anti-HSP70 or control Ab and the site of Ab application was then treated with 0.5% DNFB. Five days later, $5\times10^6$ splenocytes from these mice were transferred into naive syngeneic recipients. The recipients were then sensitized and ear challenged with DNFB. The adoptive transfer of splenocytes from HSP-treated donor mice led to significant inhibition (**. $p < 0.001$) of CHS in the recipient naive mice compared with the control recipient mice. Results are expressed as change in auricular thickness ± SEM. There were four mice per group and each experiment was repeated twice with identical results. The data shown are from one representative experiment.

After that, they were ear challenged with the same hapten that had been applied 5 days earlier. Although mice treated with DNFB plus anti-HSP Abs and then resensitized with DNFB had a significantly suppressed response to DNFB, mice treated with DNFB plus anti-HSP Ab and then sensitized with oxazolone behaved like normal mice in their ear swelling response to oxazolone (Fig. 7). The results indicate that these animals are able to render a full immune response to other hapten and that the combination of anti-HSP Abs followed by hapten sensitization induces hapten-specific tolerance.

Tolerance to DNFB by HSP27 and HSP70 can be adoptively transferred

In other systems, tolerance to DNFB in mice is frequently accompanied by the development of regulatory T cells which inhibit the response on subsequent encounter with hapten (15, 17). To examine whether the unresponsiveness to DNFB which occurred following HSP-Ab treatment was also associated with the development of these cells, adoptive transfer studies were performed. Mice, skin painted with a sensitizing dose of DNFB following treatment with anti-HSP-Ab or species-matched control Ab, served as donors of spleen cells that were transferred to naive syngeneic recipients. These recipient animals were then sensitized and ear challenged with DNFB. Mice that received cells from animals that were unresponsive to DNFB by pretreatment with HSP-Ab developed a significantly suppressed ear swelling response ($p < 0.001$) compared with positive controls that had not received cells, but that had been immunized and ear challenged to DNFB and to negative controls that had not received cells nor had been sensitized but had been ear challenged to DNFB (Fig. 8). Furthermore, suppression could not be adoptively transferred ($p > 0.05$) with spleen cells from donors treated with species-matched control Ab before sensitization to DNFB. These results indicate that unresponsiveness to DNFB could be adoptively transferred by spleen cells.

HSP27 augments cytokine production and the induction of CHS by DCs

There is evidence to indicate that HSPs augment the presentation of Ag to T cells (23–26). Experiments were therefore conducted to determine whether the modulation of CHS response by HSPs occurred by influencing the function of DCs. Initial studies in this regard revealed that topical administration of anti-HSP27 and anti-HSP70 Abs had no significant effect on densities of epidermal Langerhans cells and there was no difference on the migration of DCs to regional lymph nodes after hapten application (data not shown). Studies were next performed in which BMDC were stimulated with HSP27 protein for 24 h and then evaluated for the production of IL-1$\beta$, IL-12p35, IL-23p19, and IL-12p40, all of which are involved in the presentation of hapten to T cells.

To exclude the possibility that any changes in cytokine production were caused by contamination by LPS, polymyxin B was added to cultures. The addition of HSP27 to cultures augmented the production of IL-1$\beta$, IL-12p35, IL-12p40, IL-6, and TNF-$\alpha$ but not IL-23p19 in C3H/HeN mice (Fig. 9).

Several reports have shown that recombinant HSPs are frequently contaminated with TLR ligands (27, 28). To determine whether this was the case in our system, cultures were treated with both recombinant HSP27 protein and Abs to HSP27 at the same time. The cultures were then examined for production of IL-12p35,
IL-12p40, and IL-23p19. Treatment of cultures increased production of those cytokines, whereas addition of Abs to HSP27 abrogated that response, indicating that it was HSP27 that stimulated the BMDC to produce the cytokines rather than a contaminant in the HSP27 preparation (Fig. 10).

Requirement of functional TLR4 on DCs for HSP27-induced cytokine production and augmentation of the induction of CHS

Studies were also conducted to evaluate the contribution of TLR4 to the augmented cytokine response in DCs elicited by HSP27. To accomplish this, BMDC from C3H/HeJ mice, which have a functional deficiency in TLR4 signaling due to a mutation in the TLR4 gene, were compared with BMDC from C3H/HeN mice, which have normal TLR4 signaling (Fig. 9). In contrast to BMDC from C3H/HeN mice, there was no augmentation of IL-12p35 or IL-12p40 and only a modest increase in IL-1β, TNF-α, and IL-6 in BMDC from C3H/HeJ mice. Even for IL-1β, TNF-α and IL-6, HSP27-induced production was significantly less than in BMDC from C3H/HeN mice. IL-23p19, however, was significantly increased in BMDC from C3H/HeJ following treatment with HSP27, whereas levels of this cytokine were unaffected in BMDC from C3H/HeN mice.

Treatment of hapten-conjugated BMDC with HSP27 augments their contact-sensitizing capacity

We used DNBS-conjugated HSP27-treated BMDC from C3H/HeN and C3H/HeJ mice to immunize naive C3H/HeN and C3H/HeJ recipients. HSP27-stimulated DNBS-labeled DCs from C3H/HeN mice were much more proficient at immunizing both C3H/HeN and C3H/HeJ mice to DNFB than control DCs labeled with DNBS but not treated with HSP27 (Fig. 11). In contrast, HSP27-stimulated DNBS-labeled DCs from C3H/HeJ mice were comparable to control DCs labeled with DNBS (Fig.
These results indicated that HSP27 alters the immunizing capacity of DCs through a TLR4-dependent process in vivo.

**Discussion**

Our results suggest that the initial steps that occur during the induction of CHS responses are more complex than previously conceptualized. Traditionally, it was thought that haptenens were taken up by Langerhans cells and other cutaneous DCs, proinflammatory cytokines were produced, and following migration of DCs to regional lymph nodes, presentation of Ag to subpopulations of T lymphocytes occurred (29, 30). It now seems likely that HSPs and elements of the innate immune system play a much greater role in the initial stages of this process than previously thought. Using an in vivo model of allergic CHS, we found that HSP27 and HSP70 are key participants in the induction of immune responses to topically applied haptenens. When Abs to HSP27 and/or HSP70 were applied to the same site, the induction of CHS was suppressed and Ag-specific immunological unresponsiveness developed. Further analysis showed that incubation of DCs with recombinant HSP27 augmented the production of IL-1β, IL-12p35, and IL-12p40 and those cells were much more proficient at immunizing animals to DNFB. Moreover, the effect of HSP27 was mediated through the TLR4 pathway, since increased production of IL-1β, IL-12p35, and IL-12p40 augmented the capacity of DCs from C3H/HeJ mice to initiate CHS responses, but this augmentation did not occur in DCs of C3H/HeJ mice, which have a mutation in the TLR4 gene. These findings are consistent with the hypothesis that following topical application of hapten, the induction of CHS involves HSPs, which in turn activate TLR4 in DCs. TLR4 activation then serves as a stimulus for production of IL-1β, IL-12p35, and IL-12p40 by DCs, which increases their effectiveness at initiating T cell-mediated immune responses and controls the types of T cells that elicit and regulate the CHS response.

We became interested in investigating the in vivo contribution of HSPs 27 and 70 to CHS responses when we found that large amounts of these molecules were constitutively expressed in the skin of mice (6). In vitro studies have implicated the role of HSPs in adaptive and innate immune responses (5, 31). These evolutionarily conserved proteins chaperone antigenic moieties into the appropriate intracellular channels in DCs for presentation of Ag to T cells. They also promote DC maturation and they stimulate DC production of IL-1α, IL-12p35, and IL-12p40, all of which are known to promote Th1 and Tc1 cell-mediated immune responses. The immunomodulatory properties of HSPs have been exploited to stimulate immune responses by incorporating them into vectors used for vaccination against viral and tumor Ags (32–34). Moreover, HSP70 peptide complexes isolated from the brains of experimental autoimmune encephalomyelitis mice have been used to promote NK-induced tolerance to the disease in healthy mice (35). HSP70 has previously been shown to function in association with MHC class I and II molecules as part of the endogenous pathway of Ag presentation. HSP70 is capable of binding to antigenic peptides and markedly increases the efficiency of MHC class I and II presentation (36). HSPs are expressed in all organisms and in different subcellular compartments (37). The ability of HSPs to bind antigenic peptides and deliver them to APCs forms the basis for their potential role in the generation of peptide-specific T lymphocyte responses. New biochemical and structural studies have recently emerged to support the role of HSPs in some, but not all, models of Ag processing and presentation. Ag recognition by TLRs results in activation of the innate immune system and leads to the secretion of many inflammatory mediators such as TNF-α, IL-6, and several chemokines. Therefore, innate immunity is likely to play an important role both in the initiation and perpetuation of the inflammatory processes. It has been demonstrated that two members of the small HSP family, A crystallin and HSPB8, were able to activate DCs by inducing maturation and cytokine production in a rheumatoid arthritis model (38). Toxoplasma gondii-derived HSP70 (T. gondii HSP70) has also been shown to stimulate murine DC maturation via TLR4 through the MyD88-independent signal transduction cascade (39).

The contribution of HSPs to in vivo models of autoimmune and inflammatory disease has received little attention. These proteins are overexpressed in the synovial tissue of rheumatoid arthritis patients and in involved tissues of animals with experimental autoimmune encephalitis and collagen-induced arthritis (35, 38, 40). Our experiments indicate that a deficiency of HSPs in vivo will alter the T cell repertoire that develops in response to hapten. Greater numbers of immunoregulatory T cells and fewer effector T cells developed under conditions in which HSP27 was deficient and this was associated with a shift in the balance of IL-12 and IL-23 that were produced in response to hapten.

The role of TLR4 in the biologic activity of HSPs is not without precedent. Asea et al. (41) have previously shown that TLR2 and TLR4 are required for cytokine production by purified human monocytes and the THP-1 monocyte cell line in response to HSP70. HSP70-induced IL-12 production by DCs also has been shown to require TLRs (41). In addition, Flohé et al. (42) have shown that HSP60 treatment of BMDC results in their maturation and release of TNF-α, IL-12, and IL-1β. However, DCs from C3H/HeJ mice with a mutation at the TLR4 locus failed to respond to HSP60. In this study, we were able to demonstrate that TLRs are required for production of these cytokines in DCs and that this has consequences in vivo.

Our findings highlight the complex interplay between the adaptive and innate immune system during the early stages of the development of CHS involving HSPs, TLRs, and production of cytokines known to augment presentation of Ag to T cells. In support of this concept are the findings of Di Nardo et al. (43), who have shown that cathelicidins, antimicrobial peptide components of the innate immune system, inhibit the development of DNFB CHS. Cathelicidins are antimicrobial peptides that have been shown to have both pro- and anti-inflammatory activities; with respect to CHS, they interfere with DNFB-induced activation of TLR4. These findings are consistent with our results and provide additional evidence that the cellular composition of the inflammatory response with respect to regulatory T cells, effector T cells, and the cytokines that they produce is determined at least in part by the different types and concentrations of molecules of the innate immune system that are present following the skin’s initial encounter with Ag.

Many aspects of the immunological consequences of a localized deficiency of HSP27 and HSP70 in the skin are reminiscent of the effect of low doses of UV radiation on cutaneous immune responses. Like UV exposure, reducing the activity of HSP27 and HSP70 inhibited the induction of CHS. In both cases, this was due to a reduction in the Ag-presenting capacity in a confined area of skin. Also in both systems, application of hapten to the UV or HSP Ab-treated site resulted in Ag-specific unresponsiveness (2). These findings raise the possibility that alterations in the expression of HSP27 and HSP70 occur after UV exposure and that such alterations contribute to UV-induced immune suppression.

Our findings indicate that treatment of DCs with HSP27 resulted in the production of several cytokines that are involved in the Ag presentation process. Although it is tempting to attribute the defect in Ag presentation that we observed in HSP-deficient skin solely to an inability to synthesize these cytokines, we are mindful of the
fact that HSPs have additional effects on APCs, including the channeling of Ags into the appropriate pathways for Ag processing and display on MHC proteins, the maturation of DCs, and the production of other cytokines.

Significant progress has been made in elucidating the cellular and molecular mechanisms involved in the immune response to hapten applied topically to the skin. The finding that HSPs participate in the induction of CHS means that they may be attractive targets with which to manipulate the immune response to cutaneous Ags. Addition of HSPs may increase immune responses and therefore may be useful as adjuvants for vaccination, whereas inhibition of their activity may be beneficial in the prevention of autoimmune and immunological hypersensitivity diseases of the skin such as allergic CHS.

**Disclosures**

The authors have no financial conflict of interest.

**References**


